Conversations Matter: Discussing The Impact of Care Partner Burden When Caring For Individuals Living With Agitation associated With Alzheimer’s Dementia (AAD)
Individuals living with Alzheimer’s dementia often experience cognitive, behavioral, and functional impairments resulting in the need for professional or non-professional care partner support1. Behavioral or neuropsychiatric symptoms, such as agitation, have been reported to be particularly burdensome2 and are associated with reduced ability to work, burnout, and poor health outcomes among care givers3. Geriatric psychiatrist, Dr. Marc Agronin, and care partner, Carrie Shaw, share their unique perspectives and experiences with care partner burden and discuss the importance of communicating these concerns with a healthcare provider.
Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine
Carrie Shaw, MD
CEO & Founder of Embodied Labs
Miranda Fisher, PhD (OPDC)
Medical Science Liaison
References:
- McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y (2010) Dependence as a unifying construct in defining Alzheimer’s disease severity. Alzheimers Dement 6, 482-4932.
- Schein J, et al. J Alzheimers Dis. 2022;88(2):663-677
- Schmidt SG, Dichter MN, Palm R, Hasselhorn HM. Distress experienced by nurses in response to the challenging behaviour of residents – evidence from German nursing homes. J Clin Nurs. 2012 Nov;21(21-22):3134-42. doi: 10.1111/jocn.12066. PMID: 23083388.
Marc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Miranda Fisher, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.
Related Resources
Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer’s Dementia (AAD)
On-Demand Webinar-
Exploring Post-Traumatic Stress Disorder: Treatment Landscape & Unmet Needs Part 2
This part 2, on-demand webinar, examines the current PTSD treatment landscape, including discussions on both psychotherapy and pharmacotherapy. In addition, presenters review limitations and key considerations in the treatment of…